On the public citation graph

Are Transglutaminase 2 Inhibitors Able to Reduce Gliadin-Induced Toxicity Related to Celiac Disease? A Proof-of-Concept Study

https://doi.org/10.1007/s10875-012-9745-5
0 signed · 87 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/1521-4141(200105)31:5<1317::aid-immu1317>3.0.co;2-iopenalex-snapshot
T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase
inferredcites →https://doi.org/10.1002/jps.21305openalex-snapshot
Simulation Modelling of Human Intestinal Absorption using Caco-2 Permeability and Kinetic Solubility Data for Early Drug Discovery
inferredcites →https://doi.org/10.1007/s00418-004-0668-yopenalex-snapshot
Role of transglutaminase�1 in stabilisation of intercellular junctions of the vascular endothelium
inferredcites →https://doi.org/10.1016/0887-2333(94)00212-dopenalex-snapshot
Cytotoxic effect of prolamin-derived peptides on in vitro cultures of cell line Caco-2: Implications for coeliac disease
inferredcites →https://doi.org/10.1016/j.bbamcr.2011.09.012openalex-snapshot
Transglutaminase 2: A molecular Swiss army knife
inferredcites →https://doi.org/10.1016/j.bmcl.2008.09.006openalex-snapshot
Synthesis of potent water-soluble tissue transglutaminase inhibitors
inferredcites →https://doi.org/10.1016/j.febslet.2005.07.066openalex-snapshot
Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins
inferredcites →https://doi.org/10.1016/j.febslet.2005.08.017openalex-snapshot
Corrigendum to “Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins FEBS (29865)” [FEBS Letters 579 (2005) 4851–4855]
inferredcites →https://doi.org/10.1016/j.humimm.2009.04.006openalex-snapshot
Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment
inferredcites →https://doi.org/10.1016/s0016-5085(98)70008-3openalex-snapshot
Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease
inferredcites →https://doi.org/10.1016/s0140-6736(03)13803-2openalex-snapshot
Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease
inferredcites →https://doi.org/10.1038/ajg.2011.80openalex-snapshot
IL-15 Interferes With Suppressive Activity of Intestinal Regulatory T Cells Expanded in Celiac Disease
inferredcites →https://doi.org/10.1038/nm0698-713openalex-snapshot
Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease
inferredcites →https://doi.org/10.1038/sj.cdd.4401816openalex-snapshot
Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth
inferredcites →https://doi.org/10.1042/bj20021234openalex-snapshot
Transglutaminases: Nature’s biological glues
inferredcites →https://doi.org/10.1053/gast.2000.18149openalex-snapshot
Interleukin 15 mediates epithelial changes in celiac disease
inferredcites →https://doi.org/10.1053/j.gastro.2005.07.054openalex-snapshot
Unexpected Role of Surface Transglutaminase Type II in Celiac Disease
inferredcites →https://doi.org/10.1053/j.gastro.2008.03.023openalex-snapshot
Gliadin Induces an Increase in Intestinal Permeability and Zonulin Release by Binding to the Chemokine Receptor CXCR3
inferredcites →https://doi.org/10.1080/003655202753387338openalex-snapshot
Living with Coeliac Disease: Controlled Study of the Burden of Illness
inferredcites →https://doi.org/10.1080/00365520701452217openalex-snapshot
Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit
inferredcites →https://doi.org/10.1080/00365520902898119openalex-snapshot
Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function afterin vitrogliadin insult
inferredcites →https://doi.org/10.1080/07853890902878138openalex-snapshot
Enzymatic detoxification of gluten by germinating wheat proteases: Implications for new treatment of celiac disease
inferredcites →https://doi.org/10.1111/j.1365-2249.2008.03635.xopenalex-snapshot
Live probioticBifidobacterium lactisbacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture
inferredcites →https://doi.org/10.1111/j.1365-2249.2008.03662.xopenalex-snapshot
Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes
inferredcites →https://doi.org/10.1111/j.1365-2249.2010.04317.xopenalex-snapshot
Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A
inferredcites →https://doi.org/10.1111/j.1365-2796.2011.02376.xopenalex-snapshot
Novel therapies for coeliac disease
inferredcites →https://doi.org/10.1136/gut.2005.069385openalex-snapshot
Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease
inferredcites →https://doi.org/10.1136/gut.2005.086637openalex-snapshot
Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease
inferredcites →https://doi.org/10.1159/000324456openalex-snapshot
Lower Expression of Tight Junction Protein 1 Gene and Increased FOXP3 Expression in the Small Bowel Mucosa in Coeliac Disease and Associated Type 1 Diabetes Mellitus
inferredcites →https://doi.org/10.1165/rcmb.2008-0270ocopenalex-snapshot
Extracellular Matrix Influences Alveolar Epithelial Claudin Expression and Barrier Function
inferredcites →https://doi.org/10.1172/jci106108openalex-snapshot
Organ culture of mucosal biopsies of human small intestine
inferredcites →https://doi.org/10.1186/1471-2172-9-6openalex-snapshot
Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits
inferredcites →https://doi.org/10.1242/jcs.110.19.2461openalex-snapshot
Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin
inferredcites →https://doi.org/10.1309/dtyr-a91g-8r0k-tm8mopenalex-snapshot
Altered Expression, Localization, and Phosphorylation of Epithelial Junctional Proteins in Celiac Disease
inferredcites →https://doi.org/10.1371/journal.pone.0017039openalex-snapshot
Gliadin-Mediated Proliferation and Innate Immune Activation in Celiac Disease Are Due to Alterations in Vesicular Trafficking
inferredcites →https://doi.org/10.4049/jimmunol.177.6.4178openalex-snapshot
Gliadin-Specific Type 1 Regulatory T Cells from the Intestinal Mucosa of Treated Celiac Patients Inhibit Pathogenic T Cells

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4195767openalex-extracted
inferred← citeshttps://doi.org/10.1007/978-3-319-17169-2_40openalex-snapshot
Celiac Disease
inferred← citeshttps://doi.org/10.1007/s11095-012-0951-xopenalex-snapshot
Celiac Disease: A Challenging Disease for Pharmaceutical Scientists
inferred← citeshttps://doi.org/10.1007/s40124-018-0154-yopenalex-snapshot
Celiac Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-420220-7.00003-1openalex-snapshot
Treatment of Celiac Disease
inferred← citeshttps://doi.org/10.1016/b978-0-443-13359-6.00013-3openalex-snapshot
Putative therapeutic targets in celiac disease
inferred← citeshttps://doi.org/10.1016/j.coph.2015.09.002openalex-snapshot
Pharmacological approaches in celiac disease
inferred← citeshttps://doi.org/10.1016/j.dld.2019.11.010openalex-snapshot
Therapeutic options for coeliac disease: What else beyond gluten-free diet?
inferred← citeshttps://doi.org/10.1016/j.exer.2022.109338openalex-snapshot
The TGM2 Inhibitor Cysteamine Hydrochloride Does Not Impact Corneal Epithelial and Stromal Wound Healing in Vitro and in Vivo
inferred← citeshttps://doi.org/10.1016/j.gtc.2018.09.011openalex-snapshot
Nondietary Therapies for Celiac Disease
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.112020openalex-snapshot
Potential therapeutic options for celiac Disease: An update on Current evidence from Gluten-Free diet to cell therapy
inferred← citeshttps://doi.org/10.1016/j.jcmgh.2019.04.017openalex-snapshot
Novel Nondietary Therapies for Celiac Disease
inferred← citeshttps://doi.org/10.1016/j.jff.2019.03.039openalex-snapshot
Procyanidin B2 rich cocoa extracts inhibit inflammation in Caco-2 cell model of in vitro celiac disease by down-regulating interferon-gamma- or gliadin peptide 31-43-induced transglutaminase-2 and interleukin-15
inferred← citeshttps://doi.org/10.1017/s0954422416000019openalex-snapshot
Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel
inferred← citeshttps://doi.org/10.1038/nrgastro.2013.141openalex-snapshot
Advances in the treatment of coeliac disease: an immunopathogenic perspective
inferred← citeshttps://doi.org/10.1038/s41598-017-14845-4openalex-snapshot
The gliadin peptide 31-43 exacerbates kainate neurotoxicity in epilepsy models
inferred← citeshttps://doi.org/10.1080/13543784.2018.1438407openalex-snapshot
Investigational drug therapies for coeliac disease – where to from here?
inferred← citeshttps://doi.org/10.1080/1744666x.2021.1880320openalex-snapshot
An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications
inferred← citeshttps://doi.org/10.1080/1744666x.2021.2006636openalex-snapshot
Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis
inferred← citeshttps://doi.org/10.1080/17460441.2019.1642321openalex-snapshot
Challenges to drug discovery for celiac disease and approaches to overcome them
inferred← citeshttps://doi.org/10.1080/17512433.2016.1200463openalex-snapshot
Current and novel therapeutic strategies in celiac disease
inferred← citeshttps://doi.org/10.1097/mog.0000000000000041openalex-snapshot
Advances in coeliac disease
inferred← citeshttps://doi.org/10.1097/mpg.0000000000001312openalex-snapshot
Celiac Disease and Wheat Intolerance Syndrome
inferred← citeshttps://doi.org/10.1111/1750-3841.13612openalex-snapshot
Physiopathology and Management of Gluten‐Induced Celiac Disease
inferred← citeshttps://doi.org/10.1155/2014/714561openalex-snapshot
Biological Functionalities of Transglutaminase 2 and the Possibility of Its Compensation by Other Members of the Transglutaminase Family
inferred← citeshttps://doi.org/10.12873/444garciaopenalex-snapshot
Patologías relacionadas con el gluten: un auténtico desafío para la seguridad alimentaria.
inferred← citeshttps://doi.org/10.1517/13543784.2014.916274openalex-snapshot
Current status of drugs in development for celiac disease
inferred← citeshttps://doi.org/10.1517/14728214.2014.959490openalex-snapshot
Emerging drugs for coeliac disease
inferred← citeshttps://doi.org/10.1517/14728222.2014.985207openalex-snapshot
Transglutaminase as a therapeutic target for celiac disease
inferred← citeshttps://doi.org/10.1517/17460441.2013.761203openalex-snapshot
Latestin vitroandin vivomodels of celiac disease
inferred← citeshttps://doi.org/10.1586/17474124.2015.1033399openalex-snapshot
Celiac disease 2015 update: new therapies
inferred← citeshttps://doi.org/10.2340/00015555-2849openalex-snapshot
Ex vivo Culture of Duodenal Biopsies from Patients with Dermatitis Herpetiformis Indicates that Transglutaminase 3 Antibody Production Occurs in the Gut
inferred← citeshttps://doi.org/10.3109/08820139.2013.777074openalex-snapshot
Current Trends and Investigative Developments in Celiac Disease
inferred← citeshttps://doi.org/10.31390/gradschool_theses.1716openalex-snapshot
The Economic Burden of Gluten-Free Products and the Potential of Dietary Inhibitors of Transglutaminase-2
inferred← citeshttps://doi.org/10.32725/jab.2026.005openalex-snapshot
Oxaliplatin-induced testicular toxicity is associated with transglutaminase-4 upregulation, hormonal dysregulation, and inflammatory responses
inferred← citeshttps://doi.org/10.3389/fnut.2019.00187openalex-snapshot
MAGI2 Gene Region and Celiac Disease
inferred← citeshttps://doi.org/10.3389/fnut.2020.00152openalex-snapshot
Celiac Disease and Non-celiac Wheat Sensitivity: State of Art of Non-dietary Therapies
inferred← citeshttps://doi.org/10.3390/foods14010076openalex-snapshot
Gluten-Free Diet Adherence Evaluation in Adults with Long-Standing Celiac Disease
inferred← citeshttps://doi.org/10.3390/foods14060959openalex-snapshot
Celiac Disease—Narrative Review on Progress in Celiac Disease
inferred← citeshttps://doi.org/10.3390/ijms21103673openalex-snapshot
Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease
inferred← citeshttps://doi.org/10.3390/ijms23147513openalex-snapshot
Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy
inferred← citeshttps://doi.org/10.3390/ijms24054795openalex-snapshot
Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies
inferred← citeshttps://doi.org/10.3390/medicina60101650openalex-snapshot
Coeliac Disease in Children—A Clinical Review Including Novel Treatment Agents
inferred← citeshttps://doi.org/10.3390/nu10060755openalex-snapshot
Extra-Intestinal Manifestation of Celiac Disease in Children
inferred← citeshttps://doi.org/10.3748/wjg.v21.i30.9055openalex-snapshot
Calcium glycerophosphate preserves transepithelial integrity in the Caco-2 model of intestinal transport
inferred← citeshttps://doi.org/10.3889/oamjms.2022.11024openalex-snapshot
Celiac Disease: Disease Models in Understanding Pathogenesis and Search for Therapy
inferred← citeshttps://doi.org/10.3926/oms.254openalex-snapshot
Celiac Treatments, Adjuvant Therapies and Alternatives to the Gluten-Free Diet
inferred← citeshttps://doi.org/10.4103/ijp.ijp_679_19openalex-snapshot
Novel targets for drug discovery in celiac disease
inferred← citeshttps://doi.org/10.5114/pg.2014.47503openalex-snapshot
Non-dietary methods in the treatment of celiac disease
inferred← citeshttps://doi.org/10.5336/intermed.2022-90367openalex-snapshot
Molecular Diagnostic Tests and Pharmacological Therapy Approaches in Celiac Disease: A Systematic Review
inferred← citeshttps://doi.org/10.7759/cureus.84901openalex-snapshot
Role of Regulatory T Cells and Transglutaminase 2 Inhibitors in Celiac Disease: A Systematic Review
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.